जीन एडिटिंग की संपूर्ण मार्गदर्शिका।
★
मेनू
होम जानें समाचार
अन्वेषण करें तकनीकें रोग उपचार क्लिनिकल ट्रायल्स कंपनियाँ वैज्ञानिक Genes शोध संस्थाएँ
चिकित्सा से परे कृषि नैतिकता निवेश विश्व मानचित्र
जानें और टूल्स यहाँ से शुरू करें शब्दावली A–Z तकनीकों की तुलना करें समयरेखा सूचियाँ और रैंकिंग AI एजेंट्स ★ सहेजा गया API
के बारे में हमारे बारे में कार्यपद्धति डेटा स्रोत संपादकीय नीति संपर्क करें अस्वीकरण

निर्देशित दृश्य
जेनेटिक्स में नए हैं? ब्राउज़ करते समय हम हर शब्द को सरल भाषा में समझाते हैं। वही पेज, बस मदद पहले से मौजूद।

विशेषज्ञ दृष्टिकोण
आप जीव विज्ञान पहले से जानते हैं। बस सामग्री, साफ़ और संक्षिप्त, कोई अतिरिक्त स्पष्टीकरण नहीं। यह डिफ़ॉल्ट व्यू है।

इंटरफ़ेस भाषा
Light mode

Gene-editing समाचार

67 stories held Section: Treatments हर headline अपने मूल publisher से जुड़ी है यहाँ कुछ भी हमने नहीं लिखा
ये headlines इस साइट से बाहर जाती हैं

CRISPR Decoded अपनी कोई खबर नहीं देता। नीचे दी गई हर headline उसके बगल में लिखे publisher की है और उनकी वेबसाइट पर नई tab में खुलती है, जहाँ उनकी शर्तें, paywalls और tracking लागू होती हैं। हम आपको भेजने से पहले पुष्टि करेंगे।

STAT

STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down

Recent deaths are setbacks in drug companies’ interest in applying cancer therapy strategies to autoimmune diseases.

Treatments Oct 27, 2026 Read at STAT ↗ Cancer
Oct 27, 2026
Oct 23, 2026
Oct 20, 2026
Oct 17, 2026
Oct 16, 2026
09

Designing the Ecosystem for CGT Success

This proceedings eBook, developed in partnership with GEN and Cincinnati Children’s Hospital Applied Gene and Cell Therapy Center, captures perspectives and lessons from The Cell Summit ’26…

GEN — Genetic Engineering News Treatments
Oct 15, 2026
Oct 14, 2026
Oct 12, 2026
Oct 7, 2026
Oct 6, 2026
17

The Epitranscriptome Heads Toward Clinical Necessity

Short-read RNA sequencing reporting the modifications that alter protein output is starting to make epitranscriptomics indispensable for patient selection in precision medicines. The post…

GEN — Genetic Engineering News Treatments
Oct 1, 2026
Sep 30, 2026
Sep 29, 2026
Sep 28, 2026
Sep 24, 2026
Sep 23, 2026
Sep 21, 2026
28

Advancing Cell Therapy for Cardiovascular Disease

In this GEN webinar, our expert speaker Joshua Michael Hare, MD, will examine how therapeutically relevant research is helping shape the development of cell therapies for cardiovascular…

GEN — Genetic Engineering News Treatments
Sep 18, 2026
Sep 17, 2026
Sep 16, 2026
Sep 11, 2026
Sep 10, 2026
Sep 9, 2026
Sep 8, 2026
Sep 5, 2026
Sep 3, 2026
Sep 2, 2026
Sep 1, 2026
Aug 30, 2026
Aug 28, 2026
Aug 27, 2026
Aug 26, 2026
Aug 25, 2026
Aug 19, 2026
55

Cell Therapy Company Aims to Pioneer Analytics Automation

BlueRock says it’s helping advance the cell therapy industry by developing an automated system for analytical auditing. They say it’s among the few systems specifically designed for this…

GEN — Genetic Engineering News Treatments
Aug 18, 2026
Aug 17, 2026
Aug 12, 2026
Jul 26, 2026
Sep 7, 2025
63

Scientists just made CRISPR three times more effective

Northwestern scientists have developed a new nanostructure that supercharges CRISPR’s ability to safely and efficiently enter cells, potentially unlocking its full power to treat genetic…

Science Daily — Gene Therapy Treatments
May 21, 2025
May 12, 2025
Apr 9, 2025
66

Engineering smart delivery for gene editors

A research team has developed an advanced delivery system that transports gene-editing tools based on the CRISPR/Cas9 gene-editing system into living cells with significantly greater…

Science Daily — Gene Therapy Treatments CRISPR-Cas9
Jan 28, 2025

पत्रकारिता नहीं: घर में लिखा गया

CRISPR Decoded ब्रीफ्स

हमारे अपने database रिकॉर्ड से AI की सहायता से तैयार किए गए संक्षिप्त सारांश। इन्हें किसी और ने रिपोर्ट नहीं किया है, इन पर कोई byline नहीं है, और ठीक इसी कारण से इन्हें ऊपर की खबरों से अलग रखा गया है।

How to read the evidence levels on this site

CRISPR Decoded organises its 92 pages across four evidence levels, and the distinction matters because it signals how much human data sits behind any claim. Laboratory research, covering 5 pages, describes work done entirely in cells or computer models. No human has received anything at this stage. Preclinical research, covering 12 pages, adds animal studies but still involves no human trials. Both levels indicate that a technology or disease application is at an exploratory stage, and according to CRISPR Decoded records, conditions such as Parkinson's disease sit at laboratory research while Duchenne muscular dystrophy remains preclinical. Clinical research is the largest category, with 59 pages. It covers every phase of human trials, from first-in-human Phase I studies through to Phase III registrational programmes. Being in clinical research means human data exists, but it does not mean a therapy is proven safe, effective or available. Approved treatment, covering 16 pages, is reserved for therapies that have cleared regulatory review. According to CRISPR Decoded records, only one gene editing therapy, Casgevy, holds that status, making the approved category the narrowest and most consequential distinction of all.

16h ago

The hardest unsolved problems

Approved gene editing treatments exist today for sickle cell disease and beta thalassemia, and the records of CRISPR Decoded point to a shared reason: both diseases involve blood stem cells that can be removed from a patient, edited outside the body, and returned. This ex vivo approach sidesteps one of the hardest problems in the field, namely delivering editing machinery reliably to cells inside a living person. Casgevy, a CRISPR-Cas9 therapy, reached approval on exactly this basis. Conditions that require editing inside the body face a steeper path. The liver is relatively accessible via lipid nanoparticles, which is why ATTR amyloidosis and hereditary angioedema have reached Phase III. Tissues such as muscle, the central nervous system and the lung are harder to reach, and Duchenne muscular dystrophy, Huntington's disease and cystic fibrosis remain preclinical in these records. A 2025 death in the MAGNITUDE liver-targeting trial also illustrated a further constraint: an irreversible in vivo edit cannot be withdrawn if something goes wrong, raising the safety threshold regulators apply.

16h ago

What has changed most recently

According to CRISPR Decoded records, the most recent developments span 2023 to 2026 and range from a landmark approval to the first positive Phase 3 result for in vivo gene editing. In November 2023, the UK MHRA authorised Casgevy, a CRISPR-Cas9 therapy, for sickle cell disease and beta thalassemia, with FDA authorisation following in December 2023 and January 2024. This represents an approved treatment, the highest evidence level recorded. In 2025, results from PM359 in chronic granulomatous disease provided the first clinical evidence for prime editing, rated clinical research: prime-edited stem cells engrafted and restored immune function. That same year, a participant in the Phase 3 MAGNITUDE trial of nexiguran ziclumeran died following severe liver injury, prompting a voluntary pause and an FDA clinical hold. The hold on MAGNITUDE was later lifted. In 2026, Intellia reported positive Phase 3 results, clinical research evidence, for lonvoguran ziclumeran in hereditary angioedema, described in CRISPR Decoded records as the first successful registrational trial of in vivo gene editing, with a licence application signalled for later that year.

16h ago

Where gene editing actually stands today

As reflected in CRISPR Decoded records, one gene editing treatment has reached regulatory approval: Casgevy, a CRISPR-Cas9 therapy for sickle cell disease and beta thalassemia, authorised first by the UK MHRA in November 2023 and subsequently by the FDA. Two approved lentiviral gene-addition therapies, Lyfgenia and Zynteglo, address the same blood disorders but use a different mechanism and are not gene editing. Four gene editing programmes have reached Phase III. Nexiguran ziclumeran targets ATTR amyloidosis, lonvoguran ziclumeran targets hereditary angioedema and reported the first positive Phase III result for in vivo gene editing, risto-cel uses base editing for sickle cell disease, and BEAM-302 applies base editing to alpha-1 antitrypsin deficiency. Several earlier-stage trials cover cancer, familial hypercholesterolemia, chronic granulomatous disease and diabetes. A significant portion of the broader landscape remains preclinical or at discovery stage, including programmes for Duchenne muscular dystrophy, cystic fibrosis, hemophilia, Huntington's disease, Parkinson's disease and Alzheimer's disease, underlining how much of gene editing's potential has not yet been tested in humans.

16h ago

ये सुर्खियाँ कहाँ से आती हैं

हर वह publisher जिनसे CRISPR Decoded सामग्री लेता है, और अभी उनकी कितनी खबरें यहाँ मौजूद हैं।

प्रकाशकआलेख संग्रहीतसबसे हाल का
GEN — Genetic Engineering News 65 Oct 27, 2026
Endpoints News 50 Oct 27, 2026
Nature Genetics 30 Oct 26, 2026
STAT 24 Oct 27, 2026
Phys.org — Molecular Biology 20 Oct 27, 2026
Medical Xpress — Genetics 15 Oct 22, 2026
Science Daily — Gene Therapy 6 Sep 7, 2025
The Guardian — Genetics 6 Sep 21, 2026
Science Daily — Genes 5 Oct 7, 2026
Science Daily 2 Aug 17, 2026
New Scientist 2 Sep 25, 2026
FDA 2 Sep 17, 2026
MIT Technology Review 2 Aug 14, 2026

केवल headlines, publisher के नाम और links। लेख संबंधित publishers की संपत्ति हैं। तारीखें प्रत्येक feed द्वारा बताई गई प्रकाशन तारीखें हैं, UTC में। जहाँ छवियाँ दिखाई जाती हैं, वे publisher के सर्वर से आती हैं और उन्हीं की हैं।